Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease
Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.
Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.
What's Your Reaction?
